R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

After increasing its stake in the infectious disease testmaker last year, Altai Capital Management is now pushing OraSure Technologies to consider the sale of its entire business, along w | The hedge ...

Alcon and Lensar are walking away from a proposed acquisition deal following pushback from the Federal Trade Commission (FTC) ...

Johnson & Johnson is stepping away from its startup incubator in New York.  | The pharma is transitioning operations and management of its New York City JLABS space to the site owner, the New York ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Amanda Miller was 30 and pregnant with her second child in Hershey, Pennsylvania, when she developed depression. After she gave birth, her depression worsened. | The American Psychiatric Association ...

Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate. The reprioritization is meant to ...

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

One of the world’s largest hearing aid retailers plans to bring a top manufacturer under its roof in a major acquisition that ...

Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid ...